Oxford-AstraZeneca virus vaccine triggers antibodies in elderly
Monday, October 26, 2020
The coronavirus vaccine being developed by the University of Oxford and AstraZeneca has produced an immune response in both the elderly and young.
The vaccine triggers protective antibodies and T-cells amongst its older users, Sky News reports citing The Financial Times.
It also reports that these new findings echo results from July that show the vaccine produced "robust immune responses" among healthy adults aged between 18 and 55 years.
"The results further build the body of evidence for the safety and immunogenicity of AZD1222," an AstraZeneca spokesman said, referring to the technical name of the vaccine, Reuters reports.
It is considered a front runner in the race to produce an anti-coronavirus vaccine.
UK Health Secretary Matt Hancock has said the vaccine is expected to be ready by the first half 2021.
The vaccine was developed by Oxford University scientists and licensed to AstraZeneca in April.